【摘要】：結直腸癌是目前世界范圍內致死率極高的一種惡性腫瘤,發(fā)病率呈逐年上升的趨勢。當v-Ki-ras2 Kirsten大鼠肉瘤病毒癌基因同源物(v-Ki-ras2Kirsten rat sarcoma viral oncogene homolog,K-Ras)基因突變時患者極易出現復發(fā)和轉移,嚴重影響了直結腸癌的治療進程。耐藥是腫瘤治療中的主要問題,K-Ras基因突變型直結腸癌的耐藥問題尤其突出,且目前缺少有效的治療對策。隨著對K-Ras基因突變后,腫瘤耐藥、復發(fā)和轉移機制研究的增多,直結腸癌分子標志物不斷被發(fā)現,新型藥物及相應的聯合用藥方案不斷出現,K-Ras突變型直結腸癌的治療也愈來愈趨向合理化,但其中仍存在許多問題。因此,本文將就K-Ras突變型結直腸癌的研究近況,從其突變特征、治療難點、研究突破和未來預測等方面對K-Ras基因突變型直結腸癌的研究進展進行綜述,希望能為后續(xù)臨床治療和研究提供一些有用參考。
[Abstract]:Colorectal cancer is a malignant tumor with high mortality in the world. The incidence of colorectal cancer is increasing year by year. When v-Ki-ras2 Kirsten rat sarcoma virus oncogene congener (v-Ki-ras2Kirsten rat sarcoma viral oncogene homolog,K-Ras) gene mutation, patients are prone to recurrence and metastasis, which seriously affects the treatment process of colon cancer. Drug resistance is a major problem in the treatment of cancer. The drug resistance of K-Ras gene mutant colorectal cancer is especially prominent, and there is a lack of effective treatment strategy. With the increase of studies on the mechanism of drug resistance, recurrence and metastasis of K-Ras gene, molecular markers of colorectal cancer have been found. With the emergence of new drugs and the corresponding combination of drugs, the treatment of K-Ras mutant colorectal cancer is becoming more and more rational, but there are still many problems. Therefore, this article will review the recent research progress of K-Ras mutant colorectal cancer, including its mutation characteristics, treatment difficulties, research breakthrough and future prediction. Hope to provide some useful reference for the follow-up clinical treatment and research.
【作者單位】： 南京中醫(yī)藥大學藥學院;江蘇省中藥藥效與安全性評價重點實驗室;江蘇省中醫(yī)藥防治腫瘤協(xié)同創(chuàng)新中心;
【基金】：國家自然科學基金資助項目(編號:81673648,81673725,81573859) 江蘇省自然科學基金資助項目(編號:BK2012854) 江蘇省高校中藥學優(yōu)勢學科建設工程資助項目[編號:蘇政辦發(fā)(2014)37號文] 中國博士后科學基金資助項目(編號:2014M551639)~~
【分類號】：R735.34

【參考文獻】

相關期刊論文 前7條

1 Hakan Kocoglu;Fatih Mehmet Velibeyoglu;Mustafa Karaca;Deniz Tural;;Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer[J];World Journal of Gastrointestinal Oncology;2016年01期

2 張志強;高體云;李f，

本文編號：2268770